January 1, 2010Cardiology
Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III
Key result
Novel AHF drug development approach proposes prioritizing symptom relief and short-term mortality over surrogate endpoints.
Why the study?
Attempts to develop new therapies for acute heart failure have largely failed due to limitations in understanding pathophysiology, current therapies, new agents, and study designs.
Design
Review of clinical drug development strategies for acute heart failure
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for endpoint selection in acute HF trials; prospective validation required before adoption.
PICO
P
Population
Acute heart failure
I
Intervention / Comparator
New therapies for acute heart failure
Proposes a novel, structured approach for the clinical development of new therapies for acute heart failure, emphasizing clinically meaningful endpoints over surrogate markers in phase II and III trials.
Cite This Study
Cotter et al. (2010) conducted a review in Acute heart failure. New therapies for acute heart failure was evaluated. A novel approach for acute heart failure drug development proposes using clinically meaningful endpoints like symptom relief and short-term mortality rather than surrogate endpoints.